Butyrylcholinesterase is a potential biomarker for Sudden Infant Death Syndrome

Harrington, Carmel; Hafid, Naz Al; Waters, Karen A.

doi:10.1016/j.ebiom.2022.104041

Cited by 35 publications

(19 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Schon lange wird vermutet, dass Weckreaktionen und bestimmte Schutzreflexe wie Arousal und Gasping bei den betroffenen Säuglingen gestört sein könnten und/oder in Bauchlage nicht ausreichend wirksam werden können. Aus Australien wurde kürzlich auf der Grundlage einer Fall-Kontroll-Studie berichtet, dass vegetative Funktionen, die an die Verwertung von Acetylcholin gebunden sind, bei SIDS-Opfern gestört sein könnten [ 12 ]. Ob sich diese These in weiteren Studien bestätigen lässt, bleibt abzuwarten [ 13 ].…”

Section: Ergebnisse Und Schwerpunkte Der Letzten 5 Jahreunclassified

Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Pädiatrie“

Paditz¹,

Wiater

Ipsiroglu

et al. 2022

Somnologie

View full text Add to dashboard Cite

Section: Ergebnisse Und Schwerpunkte Der Letzten 5 Jahreunclassified

Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Pädiatrie“

Paditz¹,

Wiater

Ipsiroglu

et al. 2022

Somnologie

View full text Add to dashboard Cite

“…2−4 Butyrylcholinesterase is a less specific ChE enzyme, found mainly in the plasma, and its disruption has been linked with sudden infant death syndrome and Alzheimer's disease, potentially serving as a biomarker. 5 While cholinesterase inhibitors can serve as therapeutics, high doses found in organophosphorus pesticides and nerve agents cause cognitive decline and mortality. 6 Therefore, measuring the activity of these enzymes is important for the detection of health hazards, biomarker monitoring, studies of the cholinergic system, and the search for novel therapeutics for neurodegenerative diseases.…”

Section: ■ Introductionmentioning

confidence: 99%

Monitoring the Activity and Inhibition of Cholinesterase Enzymes using Single-Walled Carbon Nanotube Fluorescent Sensors

2022

View full text Add to dashboard Cite

Cholinesterase enzymes are involved in a wide range of bodily functions, and their disruption is linked to pathologies such as neurodegenerative diseases and cancer. While cholinesterase inhibitors are used as drug treatments for diseases such as Alzheimer and dementia at therapeutic doses, acute exposure to high doses, found in pesticides and nerve agents, can be lethal. Therefore, measuring cholinesterase activity is important for numerous applications ranging from the search for novel treatments for neurodegenerative disorders to the on-site detection of potential health hazards. Here, we present the development of a near-infrared (near-IR) fluorescent single-walled carbon nanotube (SWCNT) optical sensor for cholinesterase activity and demonstrate the detection of both acetylcholinesterase and butyrylcholinesterase, as well as their inhibition. We show sub U L–1 sensitivity, demonstrate the optical response at the level of individual nanosensors, and showcase an optical signal output in the 900–1400 nm range, which overlaps with the biological transparency window. To the best of our knowledge, this is the longest wavelength cholinesterase activity sensor reported to date. Our near-IR fluorescence-based approach opens new avenues for spatiotemporal-resolved detection of cholinesterase activity, with numerous applications such as advancing the research of the cholinergic system, detecting on-site potential health hazards, and measuring biomarkers in real-time.

show abstract

“…Universally, no definition has been accepted, and thus, SIDS is based on a diagnosis of exclusion, where no other known cause of death can be determined [ 4 ]. SIDS still remains unacceptably high [ 5 ], recorded as the leading cause of post-neonatal mortality, despite the success of the ‘back-to-sleep’ campaign, which reduced SIDS deaths by over 50–80% in the Western world [ 6 , 7 , 8 ]. During this time period, awareness of SIDS, coupled with sleep position campaigns, breastfeeding recommendations, smoking and environmental tobacco smoke recommendations, changes in death scene investigation protocols [ 3 , 9 ], and improvements in perinatal care also occurred [ 10 ], made it difficult to attribute the drop in SIDS solely to the supine sleep practice [ 9 , 10 ].…”

Section: Introductionmentioning

confidence: 99%

Development of a Risk Score to Predict Sudden Infant Death Syndrome

Polavarapu

Klonoff-Cohen

Joshi

et al. 2022

IJERPH

View full text Add to dashboard Cite

Sudden Infant Death Syndrome (SIDS) is the third leading cause of death among infants younger than one year of age. Effective SIDS prediction models have yet to be developed. Hence, we developed a risk score for SIDS, testing contemporary factors including infant exposure to passive smoke, circumcision, and sleep position along with known risk factors based on 291 SIDS and 242 healthy control infants. The data were retrieved from death certificates, parent interviews, and medical records collected between 1989–1992, prior to the Back to Sleep Campaign. Multivariable logistic regression models were performed to develop a risk score model. Our finalized risk score model included: (i) breastfeeding duration (OR = 13.85, p < 0.001); (ii) family history of SIDS (OR = 4.31, p < 0.001); (iii) low birth weight (OR = 2.74, p = 0.003); (iv) exposure to passive smoking (OR = 2.64, p < 0.001); (v) maternal anemia during pregnancy (OR = 2.07, p = 0.03); and (vi) maternal age <25 years (OR = 1.77, p = 0.01). The area under the curve for the overall model was 0.79, and the sensitivity and specificity were 79% and 63%, respectively. Once this risk score is further validated it could ultimately help physicians identify the high risk infants and counsel parents about modifiable risk factors that are most predictive of SIDS.

show abstract

Butyrylcholinesterase is a potential biomarker for Sudden Infant Death Syndrome

Cited by 35 publications

References 67 publications

Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Pädiatrie“

Aktuelle Entwicklungen in der Schlafforschung und Schlafmedizin – eine Einschätzung der AG „Pädiatrie“

Monitoring the Activity and Inhibition of Cholinesterase Enzymes using Single-Walled Carbon Nanotube Fluorescent Sensors

Development of a Risk Score to Predict Sudden Infant Death Syndrome

Contact Info

Product

Resources

About